专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL196209A ANTI PDGFR-ALPHA ANTIBODY, NUCLEIC ACID ENCODING THE SAME, VECTOR COMPRISING SAID NUCLEIC ACID, HOST CELL COMPRISING SAID VECTOR, CONJUGATE OF SAID ANTIBODY AND USE OF THE SAID ANTIBODY IN THE PREPARATION OF MEDICAMENTS 未知
公开(公告)号：IL196209A
公开(公告)日：2013-03-24
申请号：IL19620908
申请日：2008-12-25
申请人： ASTRAZENECA AB , BLAKEY DAVID CHARLES , GAZIT-BORNSTEIN GADI , YANG XIADONG , CARTLIDGE SUSAN ANN , LAING NAOMI , KANG JASPAL SINGH , FOLTZ IAN , TAYLOR LAURA
发明人： BLAKEY DAVID CHARLES , GAZIT-BORNSTEIN GADI , YANG XIADONG , CARTLIDGE SUSAN ANN , LAING NAOMI , KANG JASPAL SINGH , FOLTZ IAN , TAYLOR LAURA
摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

2. 发明专利

IL196848D0 ANTIBODIES DIRECTED TO ??V??6 AND USES THEREOF 未知
公开(公告)号：IL196848D0
公开(公告)日：2011-08-01
申请号：IL19684809
申请日：2009-02-02
申请人： ASTRAZENECA AB , FOLTZ IAN , RINKENBERGER JULIE , ALFRED AVRIL , BARRY SIMON THOMAS , BEDIAN VAHE
IPC分类号： C07K20060101
摘要： Targeted binding agents, such antibodies directed to the antigen αV&bgr;6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αV&bgr;6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.

3. 发明专利

IL222833D0 ANTIBODY OR FRAGMENT THEREOF THAT BINDS TO PDGFR-ALPHA, NUCLEIC ACID ENCODING THE SAME, VECTORS, HOST CELLS AND CONJUGATES COMPRISING SUCH ANTIBODY AND USES OF SUCH ANTIBODY IN THE MANUFACTURE OF MEDICAMENTS 未知
公开(公告)号：IL222833D0
公开(公告)日：2012-12-31
申请号：IL22283312
申请日：2012-11-01
申请人： ASTRAZENECA AB , BLAKEY DAVID CHARLES , GAZIT BORNSTEIN GADI , YANG XIADONG , CARTLIDGE SUSAN ANN , LAING NAOMI , KANG JASPAL SINGH , FOLTZ IAN , TAYLOR LAURA
摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

4. 发明专利

IL196209D0 TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF 未知
公开(公告)号：IL196209D0
公开(公告)日：2011-08-01
申请号：IL19620908
申请日：2008-12-25
申请人： ASTRAZENECA AB , BLAKEY DAVID CHARLES , GAZIT BORNSTEIN GADI , YANG XIAODONG , CARTLIDGE SUSAN ANN , LAING NAOMI , KANG JASPAL SINGH , FOLTZ IAN , TAYLOR LAURA
IPC分类号： A61K20060101
摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

5. 发明专利

IL196701D0 HUMAN ANTIBODIES TO ErbB2 未知
公开(公告)号：IL196701D0
公开(公告)日：2011-08-01
申请号：IL19670109
申请日：2009-01-25
申请人： ASTRAZENECA AB , CARTLIDGE SUSAN ANN , KANG JASPAL SINGH , FOLTZ IAN , DONG JIANYING , HICKINSON MARK
IPC分类号： C07K20060101
摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies.

6. 发明申请

WO2011130417A3 HUMAN FGF RECEPTOR AND ß-KLOTHO BINDING PROTEINS 审中-公开
标题翻译：人FGF受体和ß-KLOTHO结合蛋白
公开(公告)号：WO2011130417A3
公开(公告)日：2012-03-08
申请号：PCT/US2011032333
申请日：2011-04-13
申请人： AMGEN INC , FACHINI ROGER , FOLTZ IAN , HAN SEOG JOON , HARRIS SUSIE MIKI , HU SHAW-FEN SYLVIA , KING CHADWICK TERENCE , LI YANG , LU JI , MICHAELS MARK LEO , SUN JEONGHOON
发明人： FACHINI ROGER , FOLTZ IAN , HAN SEOG JOON , HARRIS SUSIE MIKI , HU SHAW-FEN SYLVIA , KING CHADWICK TERENCE , LI YANG , LU JI , MICHAELS MARK LEO , SUN JEONGHOON
IPC分类号： C07K16/28 , A61K39/395 , A61P3/10
CPC分类号： A61K39/3955 , C07K16/2863 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/32 , C07K2317/75 , C07K2317/92 , C07K2319/75
摘要： The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to ß-Klotho, or ß-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to ß-Klotho, or ß-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
摘要翻译：本发明提供与抗原结合蛋白和特异性结合ß-Klotho或ß-Klotho以及FGFR1c，FGFR2c，FGFR3c和FGFR4中的一种或多种的抗原结合蛋白和抗原结合蛋白-FGF21融合物相关或衍生的组合物和方法。在一些实施方案中，抗原结合蛋白和抗原结合蛋白FGF21融合物诱导FGF21样信号传导。在一些实施方案中，抗原结合蛋白或抗原结合蛋白-FGF21融合抗原结合组分是完全人，人源化或嵌合抗体，这种抗体的结合片段和衍生物，以及特异性结合ß-Klotho或ß- Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4中的一种或多种。其他实施方案提供编码这种抗原结合蛋白和抗原结合蛋白-FGF21融合体的核酸，及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备这种抗原结合蛋白的方法和抗原结合蛋白-FGF21融合物，其衍生物和多肽，以及使用这种抗原结合蛋白和抗原结合蛋白-FGF21融合体，其片段和衍生物和多肽的方法，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和相关疾病或病症。

7. 发明申请

WO2011130417A2 HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS 审中-公开
标题翻译：人FGF受体和ß-KLOTHO结合蛋白
公开(公告)号：WO2011130417A2
公开(公告)日：2011-10-20
申请号：PCT/US2011/032333
申请日：2011-04-13
申请人： AMGEN INC. , FACHINI, Roger , FOLTZ, Ian , HAN, Seog Joon , HARRIS, Susie Miki , HU, Shaw-Fen Sylvia , KING, Chadwick Terence , LI, Yang , LU, Ji , MICHAELS, Mark Leo , SUN, Jeonghoon
发明人： FACHINI, Roger , FOLTZ, Ian , HAN, Seog Joon , HARRIS, Susie Miki , HU, Shaw-Fen Sylvia , KING, Chadwick Terence , LI, Yang , LU, Ji , MICHAELS, Mark Leo , SUN, Jeonghoon
IPC分类号： C07K16/28
CPC分类号： A61K39/3955 , C07K16/2863 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/32 , C07K2317/75 , C07K2317/92 , C07K2319/75
摘要： The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
摘要翻译：本发明提供与抗原结合蛋白和特异性结合ß-Klotho或ß-Klotho以及FGFR1c，FGFR2c，FGFR3c和FGFR4中的一种或多种的抗原结合蛋白和抗原结合蛋白-FGF21融合物相关或衍生的组合物和方法。在一些实施方案中，抗原结合蛋白和抗原结合蛋白FGF21融合物诱导FGF21样信号传导。在一些实施方案中，抗原结合蛋白或抗原结合蛋白-FGF21融合抗原结合组分是完全人，人源化或嵌合抗体，这种抗体的结合片段和衍生物，以及特异性结合ß-Klotho或ß- Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4中的一种或多种。其他实施方案提供编码这种抗原结合蛋白和抗原结合蛋白-FGF21融合体的核酸，及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备这种抗原结合蛋白的方法和抗原结合蛋白-FGF21融合物，其衍生物和多肽，以及使用这种抗原结合蛋白和抗原结合蛋白-FGF21融合体，其片段和衍生物和多肽的方法，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和相关疾病或病症。

8. 发明申请

WO2010072741A9 TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREFOR 审中-公开
公开(公告)号：WO2010072741A9
公开(公告)日：2010-07-01
申请号：PCT/EP2009/067707
申请日：2009-12-21
申请人： ASTRAZENECA AB , BARRY, Simon Thomas , EBERLEIN, Catherine Anne , FOLTZ, Ian , KANG, Paul , KENDREW, Jane , ALFRED, Avril
发明人： BARRY, Simon Thomas , EBERLEIN, Catherine Anne , FOLTZ, Ian , KANG, Paul , KENDREW, Jane , ALFRED, Avril
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
摘要： The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.

9. 发明申请

WO2008112003A3 TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF 审中-公开
标题翻译：针对PDGFR-ALPHA的针对性结合剂及其用途
公开(公告)号：WO2008112003A3
公开(公告)日：2008-11-20
申请号：PCT/US2007075117
申请日：2007-08-02
申请人： ASTRAZENECA AB , LAING NAOMI , KANG JASPAL SINGH , FOLTZ IAN , GAZIT-BORNSTEIN GADI , YANG XIAO-DANG , CARTLIDGE SUSAN ANN , BLAKEY DAVID CHARLES , TAYLOR LAURA
发明人： LAING NAOMI , KANG JASPAL SINGH , FOLTZ IAN , GAZIT-BORNSTEIN GADI , YANG XIAO-DANG , CARTLIDGE SUSAN ANN , BLAKEY DAVID CHARLES , TAYLOR LAURA
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
摘要翻译：本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。

10. 发明申请

WO2007027713A3 TRAIL RECEPTOR 2 POLYPEPTIDES AND ANTIBODIES 审中-公开
公开(公告)号：WO2007027713A3
公开(公告)日：2007-03-08
申请号：PCT/US2006/033763
申请日：2006-08-28
申请人： AMGEN INC. , GLINIAK, Brian , YANG, Xiao-dong , WONG-MADDEN, Sharon , FOLTZ, Ian , FENG, Xiao , FITCH, Alison , FOSTER, Stephen , KETCHEM, Randall, R.
发明人： GLINIAK, Brian , YANG, Xiao-dong , WONG-MADDEN, Sharon , FOLTZ, Ian , FENG, Xiao , FITCH, Alison , FOSTER, Stephen , KETCHEM, Randall, R.
IPC分类号： C07K16/28 , C12N15/13 , A61K39/00
摘要： Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand ("TRAIL") Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式